John Frangioni, MD
CEO, Curadel Surgical Innovations, Inc.
Dr. Frangioni is an internationally renowned expert in molecular imaging and image-guided surgery. As CEO of Curadel Surgical Innovations he leads a talented team dedicated to the market approval of FLARE® contrast agents (drugs) under cGMP and an ICH Q10- and 21 CFR 210/211-compliant quality management system. He has also created a clinical trial infrastructure that permits multinational pivotal trials to be conducted with cost- and time-efficiency. Dr. Frangioni's group has led the field of NIR-guided surgery for over 20 years with over 800 patients studied in published clinical trials. He has also been the PI of peer-reviewed NIH research grants totaling over $61M. He was previously Professor of Medicine and Professor of Radiology at Harvard Medical School, and was board-certified in internal medicine and medical oncology. He is the recipient of Mentor of the Year at Harvard Medical School, the Edward M. Kennedy Award for Healthcare Innovation, a Visiting Professorship of the Royal Netherlands Academy of Arts and Sciences, and induction into the American Society for Clinical Investigation. Dr. Frangioni received his A.B. (Engineering Sciences) and Ph.D. (Cell Biology) from Harvard and his M.D. from Harvard and MIT's Health Science and Technology (HST) Program.